Secukinumab Dosing Regimen Influences Plaque Psoriasis Response in Heavier Patients
The efficacay, safety, and tolerability of secukinumab 300 biweekly vs very 4 weeks in heavier patients with psoriasis is evaluated.
Plaque Psoriasis
Tapinarof Reduces Severity of Plaque Psoriasis
The findings from 2 identical phase 3 trials that assessed the safety and efficacy of tapinarof 1% cream for plaque psoriasis are reviewed.
Rate of Skin Clearance Linked to Quality of Life in Children With Psoriasis
Improvement in psoriasis clearance and its effect on pediatric patients’ quality of life is reviewed.
Freedom From Disease Defined for Psoriasis
A group of European nurses, dermatologists, and patients sought to define “freedom from disease” for patients with plaque psoriasis.
Otezla Now Approved for Plaque Psoriasis Across All Severities
The approval was based on data from the phase 3 ADVANCE trial.
Freedom From Disease’ in Psoriasis Is Multicomponent Concept
Definition includes five domains of management of clinical symptoms, psychosocial elements, QoL, treatment, health care team support
Biologic Therapy May Improve Renal Function in Patients With Psoriasis
Renal function in patients with psoriasis who received biologic therapy is assessed.
Guidelines for Managing Cutaneous Lupus Erythematosus
Current, evidence-based recommendations for the management of cutaneous lupus erythematosus (CLE) in the presence or absence of systemic lupus erythematosus (SLE) in adults, young people, and children are provided.
Topical Tapinarof Reduces Severity of Plaque Psoriasis
Response rate higher but more adverse events seen at week 12 in patients with plaque psoriasis receiving tapinarof versus vehicle control
Deucravacitinib Under Review for Moderate to Severe Plaque Psoriasis
The application is supported by data from the pivotal phase 3 POETYK PSO-1 and POETYK PSO-2, which included patients with moderate to severe plaque psoriasis.
- Loading...
Loading...
Next post in Psoriasis
Loading... 
Loading...